{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:18:11Z","timestamp":1792153091884,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,5,24]],"date-time":"2012-05-24T00:00:00Z","timestamp":1337817600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1007\/s10549-012-2089-2","type":"journal-article","created":{"date-parts":[[2012,5,23]],"date-time":"2012-05-23T03:25:42Z","timestamp":1337743542000},"page":"875-880","source":"Crossref","is-referenced-by-count":138,"title":["Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010"],"prefix":"10.1007","volume":"134","author":[{"given":"Erika A.","family":"Waters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy S.","family":"McNeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Worta McCaskill","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew N.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,24]]},"reference":[{"issue":"9336","key":"2089_CR1","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","volume":"360","author":"J Cuzick","year":"2002","unstructured":"Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A et al (2002) First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360(9336):817\u2013824","journal-title":"Lancet"},{"key":"2089_CR2","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B, Constantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371\u20131388","journal-title":"J Natl Cancer Inst"},{"issue":"9122","key":"2089_CR3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(98)85012-5","volume":"352","author":"T Powles","year":"1998","unstructured":"Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M et al (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352(9122):98\u2013101","journal-title":"Lancet"},{"issue":"9122","key":"2089_CR4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0140-6736(98)85011-3","volume":"352","author":"U Veronesi","year":"1998","unstructured":"Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C et al (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352(9122):93\u201397","journal-title":"Lancet"},{"issue":"4","key":"2089_CR5","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1210\/er.2001-9002","volume":"23","author":"A Cranney","year":"2002","unstructured":"Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23(4):570\u2013578","journal-title":"Endocr Rev"},{"issue":"7","key":"2089_CR6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. J Am Med Assoc 282(7):637\u2013645","journal-title":"J Am Med Assoc"},{"issue":"2","key":"2089_CR7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","volume":"355","author":"E Barrett-Connor","year":"2006","unstructured":"Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M et al (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355(2):125\u2013137","journal-title":"N Engl J Med"},{"issue":"23","key":"2089_CR8","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","volume":"295","author":"VG Vogel","year":"2006","unstructured":"Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. J Am Med Assoc 295(23):2727\u20132841","journal-title":"J Am Med Assoc"},{"key":"2089_CR9","unstructured":"U.S. Food and Drug Administration (2007) Raloxifene hydrochloride, 9\/13\/07 approval. Available from http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/022042s000_Approv.pdf . Accessed 15 May 2012"},{"issue":"17","key":"2089_CR10","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2010.33.0258","volume":"29","author":"AN Freedman","year":"2011","unstructured":"Freedman AN, Yu B, Gail MH, Costantino JP, Graubard BI, Vogel VG et al (2011) Benefit\/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50\u00a0years or older. J Clin Oncol 29(17):2327\u20132333","journal-title":"J Clin Oncol"},{"issue":"7","key":"2089_CR11","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/jnci\/95.7.526","volume":"95","author":"AN Freedman","year":"2003","unstructured":"Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH (2003) Estimates of the number of U.S. women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 95(7):526\u2013532","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2089_CR12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1158\/1055-9965.EPI-09-0930","volume":"19","author":"EA Waters","year":"2010","unstructured":"Waters EA, Cronin KA, Graubard BI, Han PK, Freedman AN (2010) Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomark Prev 19(2):443\u2013446","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2089_CR13","unstructured":"National Center for Health Statistics (2011) Data file documentation, National Health Interview Survey, 2010 (machine readable data file and documentation). Division of Health Interview Statistics, National Center for Health Statistics, Hyattsville. Available from ftp:\/\/ftp.cdc.gov\/pub\/Health_Statistics\/NCHS\/Dataset_Documentation\/NHIS\/2010\/srvydesc.pdf . Accessed 20 April 2012"},{"key":"2089_CR14","unstructured":"National Center for Health Statistics (2006) Data file documentation, National Health Interview Survey, 2010 (machine readable data file and documentation). Division of Health Interview Statistics, National Center for Health Statistics, Hyattsville. Available from ftp:\/\/ftp.cdc.gov\/pub\/Health_Statistics\/NCHS\/Dataset_Documentation\/NHIS\/2005\/srvydesc.pdf . Accessed 20 April 2012"},{"key":"2089_CR15","unstructured":"Design and estimation for the National Health Interview Survey, 1995\u20132004. Vital and health statistics series 2. Data evaluation and methods research 130:1\u201331, (2000). Epub 2001\/11\/16"},{"key":"2089_CR16","doi-asserted-by":"crossref","DOI":"10.1002\/9781118032619","volume-title":"Analysis of health surveys","author":"EL Korn","year":"1999","unstructured":"Korn EL, Graubard BI (1999) Analysis of health surveys. Wiley, New York"},{"issue":"7","key":"2089_CR17","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s10434-001-0580-9","volume":"8","author":"ER Port","year":"2001","unstructured":"Port ER, Montgomery LL, Heerdt AS, Borgen PI (2001) Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 8(7):580\u2013585","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"2089_CR18","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1370\/afm.284","volume":"3","author":"R Taylor","year":"2005","unstructured":"Taylor R, Taguchi K (2005) Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump. Ann Fam Med 3(3):242\u2013247","journal-title":"Ann Fam Med"},{"issue":"7","key":"2089_CR19","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/01.mlr.0000129905.64831.5d","volume":"42","author":"K Malek","year":"2004","unstructured":"Malek K, Fink AK, Thwin SS, Gurwitz J, Ganz PA, Silliman RA (2004) The relationship among physicians\u2019 specialty, perceptions of the risks and benefits of adjuvant tamoxifen therapy, and its recommendation in older patients with breast cancer. Med Care 42(7):700\u2013706","journal-title":"Med Care"},{"issue":"1","key":"2089_CR20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ypmed.2004.09.041","volume":"41","author":"CP Kaplan","year":"2005","unstructured":"Kaplan CP, Haas JS, P\u00e9rez-Stable EJ, Des Jarlais G, Gregorich SE (2005) Factors affecting breast cancer risk reduction practices among California physicians. Prev Med 41(1):7\u201315","journal-title":"Prev Med"},{"issue":"1","key":"2089_CR21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11864-007-0019-z","volume":"8","author":"VG Vogel","year":"2007","unstructured":"Vogel VG (2007) Chemoprevention strategies 2006. Curr Treat Options Oncol 8(1):74\u201388","journal-title":"Curr Treat Options Oncol"},{"issue":"11","key":"2089_CR22","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3816\/CBC.2007.n.047","volume":"7","author":"JG Reeder","year":"2007","unstructured":"Reeder JG, Vogel VG (2007) Breast cancer risk management. Clin Breast Cancer 7(11):833\u2013840","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"2089_CR23","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2354.2008.00951.x","volume":"18","author":"P Blaha","year":"2009","unstructured":"Blaha P, Dubsky P, Fitzal F, Bachleitner-Hofmann T, Jakesz R, Gnant M et al (2009) Breast cancer chemoprevention\u2014a vision not yet realized. Eur J Cancer Care 18(5):438\u2013446","journal-title":"Eur J Cancer Care"},{"issue":"19","key":"2089_CR24","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1200\/JCO.2008.20.5179","volume":"27","author":"K Visvanathan","year":"2009","unstructured":"Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D et al (2009) American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27(19):3235\u20133258","journal-title":"J Clin Oncol"},{"issue":"4","key":"2089_CR25","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3322\/caac.20080","volume":"60","author":"JH Dreyfuss","year":"2010","unstructured":"Dreyfuss JH (2010) Tamoxifen infrequently used by women at risk for breast cancer. CA Cancer J Clin 60(4):204\u2013206","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"2089_CR26","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1158\/1940-6207.CAPR-10-0100","volume":"3","author":"PM Ravdin","year":"2010","unstructured":"Ravdin PM (2010) The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention. Cancer Prev Res (Phila) 3(6):686\u2013688","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1","key":"2089_CR27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1037\/1076-898X.13.1.11","volume":"13","author":"EA Waters","year":"2007","unstructured":"Waters EA, Weinstein ND, Colditz GA, Emmons K (2007) Reducing aversion to side effects in preventive medical treatment decisions. J Exp Psychol Appl 13(1):11\u201321","journal-title":"J Exp Psychol Appl"},{"key":"2089_CR28","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1002\/cncr.20981","volume":"103","author":"J Melnikow","year":"2005","unstructured":"Melnikow J, Paterniti D, Azari R, Kuenneth C, Birch S, Kupperman M et al (2005) Preferences of women evaluating risks of tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Cancer 103:1996\u20132005","journal-title":"Cancer"},{"issue":"8","key":"2089_CR29","doi-asserted-by":"crossref","first-page":"516","DOI":"10.7326\/0003-4819-150-8-200904210-00106","volume":"150","author":"LM Schwartz","year":"2009","unstructured":"Schwartz LM, Woloshin S, Welch HG (2009) Using a drug facts box to communicate drug benefits and harms: two randomized trials. Ann Intern Med 150(8):516\u2013527","journal-title":"Ann Intern Med"},{"key":"2089_CR30","doi-asserted-by":"crossref","unstructured":"Kaplan CP, Kim SE, Wong ST, Sawaya GF, Walsh JM, Perez-Stable EJ (2012) Willingness to use tamoxifen to prevent breast cancer among diverse women. Breast Cancer Res Treat 133(1):357\u2013366","DOI":"10.1007\/s10549-012-1960-5"},{"issue":"18","key":"2089_CR31","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1200\/JCO.2009.27.8077","volume":"28","author":"ME Ropka","year":"2010","unstructured":"Ropka ME, Keim J, Philbrick JT (2010) Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol 28(18):3090\u20133095","journal-title":"J Clin Oncol"},{"issue":"3","key":"2089_CR32","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10549-009-0618-4","volume":"119","author":"A Fagerlin","year":"2010","unstructured":"Fagerlin A, Zikmund-Fisher BJ, Nair V, Derry HA, McClure JB, Greene S et al (2010) Women\u2019s decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid. Breast Cancer Res Treat 119(3):613\u2013620","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"2089_CR33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1037\/a0013608","volume":"28","author":"EA Waters","year":"2009","unstructured":"Waters EA, Weinstein ND, Colditz GA, Emmons K (2009) Explanations for side effect aversion in preventive medical treatment decisions. Health Psychol 28(2):201\u2013209","journal-title":"Health Psychol"},{"issue":"1","key":"2089_CR34","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1017\/S1930297500000358","volume":"1","author":"J Amsterlaw","year":"2006","unstructured":"Amsterlaw J, Zikmund-Fisher BJ, Fagerlin A, Ubel PA (2006) Can avoidance of complications lead to biased healthcare decisions? Judgm Decis Mak 1(1):64\u201375","journal-title":"Judgm Decis Mak"},{"key":"2089_CR35","first-page":"625","volume":"52","author":"R Heisey","year":"2006","unstructured":"Heisey R, Pimlott N, Clemons M, Cummings S, Drummond N (2006) Women\u2019s views on chemoprevention of breast cancer. Can Fam Physician 52:625","journal-title":"Can Fam Physician"},{"key":"2089_CR36","first-page":"365","volume":"15","author":"DA Paterniti","year":"2005","unstructured":"Paterniti DA, Melnikow J, Henderson S, DeGregorio M, Kupperman M, Nease R (2005) \u201cI\u2019m going to die of something anyway\u201d: women\u2019s perceptions of tamoxifen for breast cancer risk reduction. Ethn Dis 15:365\u2013372","journal-title":"Ethn Dis"},{"issue":"4","key":"2089_CR37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1752-9824.2010.01068.x","volume":"2","author":"C Holmberg","year":"2010","unstructured":"Holmberg C, Daly M, McCaskill-Stevens W (2010) SI RLTD: risk scores and decision making: the anatomy of a decision to reduce breast cancer risk. J Nurs Healthc Chronic Illn 2(4):271\u2013280","journal-title":"J Nurs Healthc Chronic Illn"},{"issue":"3","key":"2089_CR38","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.2196\/jmir.1222","volume":"11","author":"EA Waters","year":"2009","unstructured":"Waters EA, Sullivan HW, Nelson W, Hesse BW (2009) What is my cancer risk? Identifying how Internet-based cancer risk calculators convey individualized risk estimates to the public. J Med Internet Res 11(3):e33","journal-title":"J Med Internet Res"},{"key":"2089_CR39","doi-asserted-by":"crossref","unstructured":"Bozovic-Spasojevic I, Azambuja E, McCaskill-Stevens W, Dinh P, Cardoso F (2011) Chemoprevention for breast cancer. Cancer Treat Rev. doi: 10.1016\/j.ctrv.2011.07.005","DOI":"10.1016\/j.ctrv.2011.07.005"},{"key":"2089_CR40","unstructured":"Anastrozole in preventing breast cancer in postmenopausal women at increased risk of breast cancer. ClinicalTrials.gov Identifier: NCT00078832"},{"key":"2089_CR41","unstructured":"Adjuvant tamoxifen compared with anastrozole compared with anastrozole in treating postmenopausal women with DCIS. ClinicalTrials.gov Identifier: NCT00072462"},{"key":"2089_CR42","unstructured":"Therapy AoTiTPwwDwaULaR. ClinicalTrials.gov Identifier: NCT00053898"},{"issue":"25","key":"2089_CR43","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","volume":"364","author":"PE Goss","year":"2011","unstructured":"Goss PE, Ingle JN, Al\u00e9s-Mart\u00ednez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J et al (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364(25):2381\u20132391","journal-title":"N Engl J Med"},{"issue":"21","key":"2089_CR44","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/jnci\/91.21.1829","volume":"91","author":"MH Gail","year":"1999","unstructured":"Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K et al (1999) Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91(21):1829\u20131846","journal-title":"J Natl Cancer Inst"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2089-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-012-2089-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2089-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T22:04:11Z","timestamp":1687471451000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-012-2089-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,24]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["2089"],"URL":"https:\/\/doi.org\/10.1007\/s10549-012-2089-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,24]]}}}